Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af sikkerheden, tolerabiliteten og effektiviteten af ​​Omega-systemet til behandling af LUTS på grund af BPH (Omega)

21. september 2026 opdateret af: ProArc Medical

Evaluering af sikkerheden, tolerabiliteten og effektiviteten af ​​Omega-systemet til behandling af nedre urinvejssymptomer på grund af benign prostatahyperplasi

This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device. The Omega arc-shaped implant is inserted by the Omega delivery system into the prostate tissue of subjects to relieve lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The study will first evaluate the Omega system on patients undergoing prostatectomy, which is not indicated for the device.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

11

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Tbilisi, Georgien
        • Tbilisi Heart Center
      • Tbilisi, Georgien
        • Todua Clinic
      • Tbilisi, Georgien, 0159
        • N(N)LE New Vision University Hospital
      • Tbilisi, Georgien
        • Israeli-Georgian Medical Research Clinic Healthycore
      • Tbilisi, Georgien
        • JSC L.Managadze National Center of Urology

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Stage 1

Inclusion Criteria:

  1. Male ≥50 years of age and ≤ 80 years old.
  2. Will undergo planned prostatectomy.
  3. Participant understands and is willing to the informed consent form.
  4. Prostate Volume between 30cc and 80cc.
  5. Prostate length ≥ 3cm

Exclusion Criteria:

  1. Unable to comply with the clinical protocol.

  2. Vulnerable population such as inmates or developmentally delayed individuals.

  3. Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure, such as:

    • Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy is not prohibited).
    • Use of alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
    • Use of 5-α-reductase inhibitors within 6 months of pre-treatment (baseline) evaluation.
  4. American Society of Anesthesiologists score (ASA) > 3.

  5. Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.

  6. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.

  7. Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.

  8. Previous rectal surgery, other than hemorrhoidectomy

  9. Current gross hematuria.

  10. Known allergy to nickel or titanium or stainless steel.

Stage 2

Inclusion Criteria:

  1. Male ≥50 years old.
  2. Suspected symptomatic benign prostatic hyperplasia (BPH).
  3. International Prostate Symptom Score (IPSS) >13.
  4. Peak flow rate ≤ 12 ml/sec (with voided volume ≥ 125ml).
  5. Participant understands and is willing to the informed consent form.
  6. Prostate Volume between 30cc and 80cc.
  7. Prostate length ≥ 3cm and ≤ 5cm

Exclusion Criteria:

  1. Diagnosed or suspected prostate cancer. If suspected, prostate cancer must be ruled out.

  2. Concomitant participation in another interventional study.

  3. Unable to comply with the clinical protocol including all the follow-up requirements.

  4. Vulnerable population such as inmates or developmentally delayed individuals.

  5. Significant comorbidities which would affect study participation.

  6. Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure ,such as:

    • Use of concomitant medications (e.g., anticholinergics, antispasmodics, or antidepressants) affecting bladder function.
    • Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure; low dose aspirin therapy not prohibited.
    • Alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
    • Taking 5-alpha reductase inhibitors (5-ARI) within 6 months (3 months for type II 5-ARI) of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study).
    • Patient is taking steroids. [Note: Patients approved for the trial who are using the above medications will continue using them after the trial, except for Alpha blockers.]
  7. Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.

  8. Compromised renal function due to obstructive uropathy.

  9. Active Urinary Tract Infection (UTI).

  10. Obstructive or protruding median lobe.

  11. American Society of Anesthesiologists score (ASA) > 3.

  12. Known neurogenic bladder or neurological disorders that might affect bladder or function.

  13. Recent myocardial infarction (less than three months).

  14. Concomitant bladder stones.

  15. Current gross hematuria.

  16. Active or history of epididymitis within the past 3 months.

  17. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.

  18. Confirmed or suspected malignancy of bladder.

  19. History or presence of strictures in the anterior urethra or bladder neck contracture or detrusor muscle spasms.

  20. Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.

  21. Bacterial prostatitis within the last 12 months.

  22. Previous rectal surgery, other than hemorrhoidectomy.

  23. Current uncontrolled diabetes (i.e., hemoglobin A1c ≥ 9%).

  24. Known allergy to nickel or titanium or stainless steel.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Omega procedure

The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.

The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Primary Safety (Stage 1 and Stage 2) - Incidence and severity of procedural and device related adverse events.
Tidsramme: 12 Months

Incidence and severity of procedural and device related adverse events.

12 Months
Primary Safety (Stage 2) - Incidence of post-operative catheterization after 7 days, up to 14 days.
Tidsramme: 2 weeks

Incidence of post-operative catheterization after 7 days, up to 14 days.

2 weeks
Efficacy (Stage 2) - Change in urinary related symptom
Tidsramme: 3 Months

Improvement in urinary related symptoms as evidenced by at least 30% decrease in International Prostate Symptom Score (A score of 0-7 indicates mild symptoms, 8-19 indicates moderate symptoms and 20-35 indicates severe symptoms)

3 Months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Effektivitet (stadie 2) - Forbedring af maksimal urinstrømshastighed som vist ved en stigning på mindst 25 % i uroflowmetri Qmax
Tidsramme: 1 måned, 3 måneder, 6 måneder og 12 måneder
1 måned, 3 måneder, 6 måneder og 12 måneder
Exploratory - Ændring i post-void residual (PVR) test
Tidsramme: 1 måned, 3 måneder, 6 måneder og 12 måneder
1 måned, 3 måneder, 6 måneder og 12 måneder
Exploratory - Incidens af inflammation, vurderet med cystoskop
Tidsramme: 6 måneder
6 måneder
Udforskende - Omega-dækning vurderet med cystoskop
Tidsramme: 6 måneder
6 måneder
Exploratory - Ændring i PSA sammenlignet med baseline
Tidsramme: 1 måned, 6 måneder og 12 måneder
1 måned, 6 måneder og 12 måneder
Exploratory - Ændring i BPHII score fra baseline
Tidsramme: 1 måned, 3 måneder, 6 måneder og 12 måneder
1 måned, 3 måneder, 6 måneder og 12 måneder
Hyppighed af gentagen invasiv behandling for symptomer på nedre urinveje (LUTS) eller stigning i dosis eller påbegyndelse af ny medicin til behandling af symptomer på BPH
Tidsramme: 12 måneder
12 måneder
Forekomst af fjernelse af enhed
Tidsramme: 12 måneder
12 måneder
Functionality (Stage 1) - Location and orientation of Omega implant in the prostate before prostatectomy is as planned: Yes/No
Tidsramme: Procedure day

Evaluating whether the outcome of the Omega implant's location and orientation turned out as the surgeon planned prior to the Omega procedure.

Procedure day
Functionality (Stage 1) - Location and depth Omega incision in the excised prostate is as planned: Yes/No.
Tidsramme: Procedure day

Evaluating whether the Omega incision location and depth outcome turned out as the surgeon planned prior to the Omega procedure.

Procedure day
Usability (Stage 1 and Stage 2) - Evaluate the usability of the device and entire process
Tidsramme: Procedure day

Evaluate the usability of the device and the entire process using the usability questionnaire (The highest score of 60 indicates that the device is extremely user-friendly, while the lowest score of 12 indicates that the device is very difficult to use)

Procedure day
Efficacy (Stage 2) - Improvement in urinary related symptoms
Tidsramme: 1 Months, 6 Months and 12 months

Evaluate the improvement in urinary-related symptoms as evidenced by a decrease of at least 30% in the IPSS score. (A score of 0-7 indicates mild symptoms, 8-19 indicates moderate symptoms and 20-35 indicates severe symptoms)

1 Months, 6 Months and 12 months
Exploratory - Change in sexual function assessments from screening to 3, 6 and 12 months using the International Index of Erectile Function (IIEF) and Male Sexual Health Questionnaire for Ejaculatory Function (MSHQ-EjD).
Tidsramme: 3 Months, 6 Months and 12 months

The IIEF-15 score ranges from 6 to 75 and is used to classify erectile dysfunction (ED).

An MSHQ-EjD score of 20 indicates the absence of ejaculatory dysfunction, while a score of 0 indicates a high level of ejaculatory dysfunction.

3 Months, 6 Months and 12 months
Exploratory - Change in VAS pain score
Tidsramme: Procedure day, 1-2 weeks and 1 month

A VAS pain score of (0-1 mm) indicates no pain,(2-4 mm) - mild pain, (4-7 mm) - moderate pain, and (7-10 mm) - severe pain.

Procedure day, 1-2 weeks and 1 month

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Frank Mastandrea, Dr, Board Member and Medical Director

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. februar 2023

Primær færdiggørelse (Faktiske)

30. april 2026

Studieafslutning (Anslået)

1. februar 2027

Datoer for studieregistrering

Først indsendt

15. februar 2023

Først indsendt, der opfyldte QC-kriterier

23. februar 2023

Først opslået (Faktiske)

7. marts 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • PA-CP-22

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .